This article was written by
Investor, entrepreneur, director. Founder of FUNanc!al, Cl1Q, MLI, Ah! Ah! Entertainment. FUNanc!al (www.funanc1al.com) provides market insight, enriches lives. Interested in a wide range of industries and technologies from biotech (synbio, crispr, mRNA, genomics, etc.) to high-tech (AI, machine learning, web, cloud, mobile, etc.), media & entertainment, fintech, and energy. Specialties include building new ventures (Internet, others), corporate mediation and conflict resolution, venture capital, mergers and acquisitions, turnaround or distressed assets, building new ecosystems and increasing the innovation throughput. Invests in all verticals, long only. Yale and Harvard grad.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of PATH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.